Literature DB >> 23138261

Exploration of optimal dosing regimens of haloperidol, a D2 Antagonist, via modeling and simulation analysis in a D2 receptor occupancy study.

Hyeong-Seok Lim1, Su Jin Kim, Yook-Hwan Noh, Byung Chul Lee, Seok-Joon Jin, Hyun Soo Park, Soohyeon Kim, In-Jin Jang, Sang Eun Kim.   

Abstract

PURPOSE: To evaluate the potential usage of D(2) receptor occupancy (D2RO) measured by positron emission tomography (PET) in antipsychotic development.
METHODS: In this randomized, parallel group study, eight healthy male volunteers received oral doses of 0.5 (n = 3), 1 (n = 2), or 3 mg (n = 3) of haloperidol once daily for 7 days. PET's were scanned before haloperidol, and on days 8, 12, with serial pharmacokinetic sampling on day 7. Pharmacokinetics and binding potential to D(2) receptor in putamen and caudate nucleus over time were analyzed using NONMEM, and simulations for the profiles of D2RO over time on various regimens of haloperidol were conducted to find the optimal dosing regimens.
RESULTS: One compartment model with a saturable binding compartment, and inhibitory E(max) model in the effect compartment best described the data. Plasma haloperidol concentrations at half-maximal inhibition were 0.791 and 0.650 ng/ml, in putamen and caudate nucleus. Simulation suggested haloperidol 2 mg every 12 h is near the optimal dose.
CONCLUSION: This study showed that sparse D2RO measurements in steady state pharmacodynamic design after multiple dosing could reveal the possibility of treatment effect of D(2) antagonist, and could identify the potential optimal doses for later clinical studies by modeling and simulation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23138261     DOI: 10.1007/s11095-012-0906-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  22 in total

Review 1.  Positron emission tomography molecular imaging for drug development.

Authors:  Paul M Matthews; Eugenii A Rabiner; Jan Passchier; Roger N Gunn
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

2.  Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol.

Authors:  Robert M Kessler; Mohammad Sib Ansari; Patrizia Riccardi; Rui Li; Karuna Jayathilake; Benoit Dawant; Herbert Y Meltzer
Journal:  Neuropsychopharmacology       Date:  2005-12       Impact factor: 7.853

Review 3.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

4.  Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride.

Authors:  Mark Slifstein; Lawrence S Kegeles; Xiaoyan Xu; Judy L Thompson; Nina Urban; John Castrillon; Elizabeth Hackett; S-A Bae; Marc Laruelle; Anissa Abi-Dargham
Journal:  Synapse       Date:  2010-05       Impact factor: 2.562

5.  Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients.

Authors:  Eiji Yukawa; Tsuyoshi Hokazono; Miho Yukawa; Ritsuko Ichimaru; Takako Maki; Kanemitsu Matsunaga; Shigehiro Ohdo; Motoaki Anai; Shun Higuchi; Yoshinobu Goto
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.

Authors:  S Kapur; G Remington
Journal:  Biol Psychiatry       Date:  2001-12-01       Impact factor: 13.382

7.  Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.

Authors:  Gianluca Nucci; Roberto Gomeni; Italo Poggesi
Journal:  Expert Opin Drug Discov       Date:  2009-06-24       Impact factor: 6.098

Review 8.  Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.

Authors:  Mats Bergström; Anders Grahnén; Bengt Långström
Journal:  Eur J Clin Pharmacol       Date:  2003-08-22       Impact factor: 2.953

9.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

Authors:  L Farde; A L Nordström; F A Wiesel; S Pauli; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1992-07

10.  D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients.

Authors:  A L Nordström; L Farde; S Nyberg; P Karlsson; C Halldin; G Sedvall
Journal:  Am J Psychiatry       Date:  1995-10       Impact factor: 18.112

View more
  3 in total

Review 1.  Integration of PKPD relationships into benefit-risk analysis.

Authors:  Francesco Bellanti; Rob C van Wijk; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

2.  Do doctors agree on doses of antipsychotic medications?

Authors:  Johan Schill; Hans Olsson
Journal:  Ther Adv Psychopharmacol       Date:  2016-08-08

3.  Secondary parkinsonism induced by hydrocephalus after subarachnoid and intraventricular hemorrhage.

Authors:  Min Cheol Chang; Min Ho Chun
Journal:  Neural Regen Res       Date:  2016-08       Impact factor: 5.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.